Latest Hotspot

Nurix Therapeutics Announces Positive NX-5948 Trial Results in CLL Patients at EHA2024

19 June 2024
3 min read

Nurix Therapeutics, Inc., a biopharmaceutical firm in the clinical stage that focuses on creating targeted protein modulation therapies for cancer and inflammatory disease patients, revealed new clinical data for NX-5948 today. NX-5948 is an orally accessible degrader of Bruton’s tyrosine kinase (BTK) and is currently being tested in a Phase 1a/b clinical trial aimed at adults with recurring or treatment-resistant B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

Dr. Kim Linton, M.B.Ch.B, MRCP, Ph.D., FRCP, a senior lecturer at the University of Manchester and a consultant at The Christie NHS Foundation Trust, who is also an investigator for the clinical trial, shared the findings during an oral session at the European Hematology Association Congress held from June 13–16, 2024, in Madrid, Spain.

"The current findings from this study on advanced patients are quite remarkable at this early stage of development, and we are hopeful that NX-5948 could represent a significant advancement for patients with relapsed CLL, especially given the emerging resistance patterns to the currently available targeted therapies," stated Dr. Linton.

Additionally, Dr. Linton presented an updated case report highlighting the response of a patient with CLL and CNS involvement who had undergone three previous therapies, including treatment with a BTK inhibitor. Following daily treatment with 100 mg, and subsequently 300 mg, of NX-5948, the patient demonstrated a deepening response nearing complete response criteria by 36 weeks, with malignant cells in the cerebrospinal fluid eliminated by week 24.

The company also presented another case report of a patient who had received eleven prior therapies, including all available BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib). After daily administration of 200 mg of NX-5948, the patient showed a response by week 8 that continued to deepen over time, with ongoing benefits observed over more than 6 months of follow-up.

"With a growing body of positive clinical data, demonstrated activity in the CNS, and a favorable safety profile, NX-5948 is emerging as a best-in-class medicine that has the potential to provide an important treatment option for patients with CLL and NHL," stated Arthur T. Sands, M.D., Ph.D., president and CEO of Nurix. "We are planning to advance quickly with the goal of initiating pivotal trial(s) with NX-5948 in 2025."

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of June 19, 2024, there are 197 investigational drugs for the BTK target, including 216 indications, 246 R&D institutions involved, with related clinical trials reaching 1325, and as many as 18390 patents.

NX-5948 is a proteolysis-targeting chimera that targets the BTK protein. It is currently in the highest phase of clinical development, which is Phase 1. The drug has been designated as a Fast Track product, indicating that it is intended to treat serious conditions and fill an unmet medical need.

图形用户界面, 文本, 应用程序, 网站

描述已自动生成

Electra Therapeutics Unveils Phase 1b Trial Results of ELA026 for sHLH at EHA2024
Latest Hotspot
3 min read
Electra Therapeutics Unveils Phase 1b Trial Results of ELA026 for sHLH at EHA2024
19 June 2024
Electra Therapeutics Reveals New Clinical Findings at EHA2024 from Active Phase 1b Trial of ELA026 for Secondary Hemophagocytic Lymphohistiocytosis (sHLH).
Read →
Cabaletta Bio Announces Positive Early Results for CABA-201 Phase 1/2 Studies in Myositis and SLE
Latest Hotspot
3 min read
Cabaletta Bio Announces Positive Early Results for CABA-201 Phase 1/2 Studies in Myositis and SLE
19 June 2024
Cabaletta Bio Releases Favorable Early Clinical Results from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Studies of CABA-201.
Read →
Kymera Therapeutics Reveals New Phase 1 Trial Data for KT-333 at EHA Event
Latest Hotspot
3 min read
Kymera Therapeutics Reveals New Phase 1 Trial Data for KT-333 at EHA Event
19 June 2024
Kymera Therapeutics Unveils Fresh Clinical Data from Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Event.
Read →
Galapagos Reveals Promising CD19 CAR-T Therapy Results for Non-Hodgkin Lymphoma at EHA 2024
Latest Hotspot
3 min read
Galapagos Reveals Promising CD19 CAR-T Therapy Results for Non-Hodgkin Lymphoma at EHA 2024
19 June 2024
Galapagos unveils promising new results for CD19 CAR-T therapy GLPG5101 in non-Hodgkin lymphoma at EHA 2024.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.